Human HLA-A*02:01&B2M&p53 (HMTEVVRRC) Tetramer Protein (MALS verified)

TP53 has been recognized as a tumor suppressor. 50% of cancers carry a TP53 mutation while many others affect other pathway components. High-copy numbers of WT p53 peptide-MHC class I complexes were detected on tumor cells as compared to low copies on normal cells. The Human HLA-A*0201 p53 (HMTEVVRRC) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and HMTEVVRRC peptide of the p53.

Human HLA-A*02:01&B2M&p53 (HMTEVVRRC) Tetramer Protein is assembled by biotinylated monomer and streptavidin. Biotinylated HLA-A*02:01&B2M&p53 (HMTEVVRRC) Complex Protein is produced by co-expression of HLA-A*02:01 and B2M loaded with p53 peptide. Biotinylated HLA-A*02:01&B2M&p53 (HMTEVVRRC) Complex Protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™) . This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™) . The protein has a calculated MW of 36.3 kDa and 13.3 kDa and 11.7 kDa. The protein migrates as 41-45 kDa, 12 kDa and 10 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

-20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower.